Lv2
168 积分 2025-09-23 加入
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
6小时前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non–Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study
7小时前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
7小时前
已完结
Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
7小时前
已完结
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
6个月前
已完结
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy
10个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
10个月前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
10个月前
已完结
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
1年前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
1年前
已完结
皖公网安备34019202002308
